Enterprise Value

-24.89M

Cash

89.43M

Avg Qtr Burn

-8.167M

Short % of Float

1.63%

Insider Ownership

7.44%

Institutional Own.

21.28%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Onvansertib (monotherapy) Details
Cancer, Small cell lung cancer

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

Onvansertib + Zytiga (abiraterone) Details
Prostate cancer, Cancer, Castration-resistant prostate cancer

Phase 2

Update

Onvansertib + Paclitaxel Details
Cancer, Triple-negative breast cancer

Phase 1/2

Data readout

Failed

Discontinued